Merck & Co., Inc. Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $17.3B | — | $5.8B | — | — | $2.32 |
| Q2 FY202510-Q · 2025-06-30 | $138.0M | — | $4.4B | — | — | $1.76 |
| Q1 FY202510-Q · 2025-03-31 | $15.5B | — | $5.1B | — | — | $2.01 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $129.5B | — | $18.2B | $51.9B |
| Q2 FY202510-Q | $117.5B | — | $8.0B | $49.0B |
| Q1 FY202510-Q | $115.1B | — | $8.6B | $48.3B |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | — | $5.8B | — | — |
| Q2 FY202510-Q | — | $4.4B | — | — |
| Q1 FY202510-Q | — | $5.1B | — | — |
Filings
(4)Methodology
Every figure on this page is pulled directly from Merck & Co., Inc.'s own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].